Clinical trials: Individual Difference
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Fatty Liver Disease, Obesity
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease…
- Trial name
- NCT05970640
- Testing
- BI 3006337
- Where
- 12 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers Type 2 Diabetes
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
The goal of this trial is to find out whether taking semaglutide tablets at different times before and after eating has a similar effect compared to the recommended dosing time.
- Trial name
- NCT04513704
- Testing
- Oral Semaglutide
- Where
- United Kingdom
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar.
- Trial name
- NCT07357740
- Testing
- CagriSema
- Where
- 61 sites in United States, Denmark and 6 more
- Sponsor
- Novo Nordisk A/S
Coronavirus
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Popular title: Clinical study of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells). Purpose of the study: Main objectives: To evaluate the immunogenicity and safety of Omicron BA.4/5-Delta…
- Trial name
- NCT06025812
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Recombinant novel coronavirus protein vaccine (CHO cells)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Coronavirus
Clinical Study of Recombinant Novel Coronavirus Vaccine
A total of 900 subjects are planned to be randomly divided into 2 doses of low-dose experimental vaccine group, 2 doses of high-dose experimental vaccine group, 2 doses of placebo group, 3 doses of low-dose experimental vaccine…
- Trial name
- NCT04466085
- Testing
- Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Healthy
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
This study is open to healthy people and people with overweight or obesity. It has 2 parts. Part A is open to healthy men between 18 and 55 years of age.
- Trial name
- NCT06352437
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study.
- Trial name
- NCT06335303
- Testing
- BI 1819479
- Where
- 163 sites in United States, Argentina and 26 more
- Volunteers
- 322 people
- Sponsor
- Boehringer Ingelheim